BCL9L

B-cell CLL/lymphoma 9-like protein (B-cell ly · Q86UU0 · BCL9L on Sugi Atlas →

283 patent compounds predicted against BCL9L, 242 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL19404295	1.00	1/20
Hydrochloric Acid (SCHEMBL30171055)	0.98	1/20
SCHEMBL19404298	0.98	1/20
Hydrochloric Acid (SCHEMBL23456245)	0.97	1/20
Hydrochloric Acid (SCHEMBL23456246)	0.97	1/20
Hydrochloric Acid (SCHEMBL30171121)	0.97	1/20
SCHEMBL19404296	0.85	1/20
SCHEMBL19404292	0.84	1/20
SCHEMBL24088846	0.84	1/20
SCHEMBL30171149	0.84	1/20
Hydrochloric Acid (SCHEMBL30392053)	0.84	1/20
SCHEMBL34461987	0.84	1/20
SCHEMBL19404256	0.83	1/20
SCHEMBL19404249	0.82	1/20
SCHEMBL19404253	0.82	1/20
Hydrochloric Acid (SCHEMBL23456231)	0.82	1/20
Hydrochloric Acid (SCHEMBL23456233)	0.82	1/20
Hydrochloric Acid (SCHEMBL30011066)	0.82	1/20
Hydrochloric Acid (SCHEMBL30011221)	0.82	1/20
SCHEMBL30171186	0.82	1/20

Clinical trials — most relevant to BCL9L by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Combination of Ibrutinib and As2O3 in the Treatment of CLL	PHASE3	UNKNOWN
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma	PHASE1/PHASE2	RECRUITING
SPC2996 in Chronic Lymphocytic Leukaemia	PHASE1/PHASE2	COMPLETED
Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis	PHASE2	COMPLETED
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors	PHASE1/PHASE2	RECRUITING
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma	PHASE1/PHASE2	RECRUITING
Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma	PHASE2	RECRUITING
Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia	PHASE1/PHASE2	COMPLETED
Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL	PHASE2	ACTIVE_NOT_RECRUITING
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL	PHASE2	ACTIVE_NOT_RECRUITING
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma	PHASE1	ACTIVE_NOT_RECRUITING
Safe Accelerated Venetoclax Escalation in CLL	PHASE1	ACTIVE_NOT_RECRUITING
CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.	PHASE1	UNKNOWN
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies	PHASE1	ACTIVE_NOT_RECRUITING
Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies	PHASE1	UNKNOWN
MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)	PHASE1	ACTIVE_NOT_RECRUITING
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma	PHASE1	COMPLETED
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)	PHASE1	COMPLETED
CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT	PHASE1	UNKNOWN
An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma	PHASE1	COMPLETED
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies	PHASE1	COMPLETED
Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)	PHASE1	COMPLETED
A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies	EARLY_PHASE1	UNKNOWN
Anti CD19 CAR-T Combined With BTKi to Treat Newly Diagnosed High-risk CLL/SLL	nan	RECRUITING
Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program	nan	COMPLETED
Potential Role of CD9 and Implication of Motility Process in Pathogenesis of TEL/ALM1-positive ALL Relapses (LAL TEL/ALM1 and CD9).	nan	COMPLETED
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a BCL9L binder may also engage these)

Protein	Name	Similarity
Q67FY2	—	1.000	Q67FY2 →
BCL9	B-cell CLL/lymphoma 9 protein	0.996	landscape →
Q9D219	—	0.993	Q9D219 →
Q67FY3	—	0.993	Q67FY3 →
A5D7F6	—	0.984	A5D7F6 →
EP300	Histone acetyltransferase p300	0.983	landscape →
B2RWS6	—	0.982	B2RWS6 →
P78337	—	0.982	P78337 →
Q9R050	—	0.982	Q9R050 →
P20009	—	0.982	P20009 →
Q9BRQ0	—	0.981	Q9BRQ0 →
Q810W5	—	0.981	Q810W5 →
D3YWE6	—	0.981	D3YWE6 →
G3V7R4	—	0.981	G3V7R4 →
O35126	—	0.980	O35126 →
Q14687	—	0.980	Q14687 →
A3RK74	—	0.980	A3RK74 →
Q9CYZ8	—	0.980	Q9CYZ8 →
A3RK75	—	0.980	A3RK75 →
P81877	—	0.980	P81877 →
Q13227	—	0.979	Q13227 →
O14497	—	0.979	O14497 →
Q7ZUK7	—	0.979	Q7ZUK7 →
Q9EPU2	—	0.979	Q9EPU2 →
Q14686	—	0.979	Q14686 →
P40645	—	0.979	P40645 →
FOXO3	Forkhead box protein O3	0.978	landscape →
Q6EUW2	—	0.978	Q6EUW2 →
P78364	—	0.978	P78364 →
Q9JLI4	—	0.978	Q9JLI4 →